[1] Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015[J]. CA Cancer J Clin, 2016, 66(2): 115-132. DOI: 10.3322/caac.21338.
[2] 孙洪鑫, 邹文斌, 廖专, 等. 中国早期胃癌临床病理特点[J]. 中国实用内科杂志, 2014, 34(6): 631634. DOI: 10.7504/nk2014050901.
[3]Sato Y, Takayama T, Sagawa T, et al. Phase Ⅱ study of S-1, docetaxel and cisplatin combination chemotherapy in patients with unresectable metastatic gastric cancer[J]. Cancer Chemother Pharmacol, 2010, 66(4): 721-728. DOI: 10.1007/s00280-009-1215-2.
[4]Hamaguchi T, Shirao K, Ohtsu A, et al. A phase Ⅱ study of biweekly mitomycin C and irinotecan combination therapy in patients with fluoropyrimidineresistant advanced gastric cancer: a report from the Gastrointestinal Oncology Group of the Japan Clinical Oncology Group (JCOG0109DI Trial)[J]. Gastric Cancer, 2011, 14(3): 226233. DOI: 10.1007/s10120-011-0030-8.
[5]Cunningham D, Allum WH, Stenning SP, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer[J]. N Engl J Med, 2006, 355(1): 11-20. DOI: 10.1056/NEJMoa055531.
[6]张勇, 彭正, 陈凛. 胃癌新辅助化疗后病理完全缓解病例生存分析[J]. 中华医学杂志, 2016, 96(20): 1582-1584. DOI: 10.3760/cma.j.issn.0376-2491.2016.20.008.
[7]Lordick F, Ott K B, Krause BJ, et al. PET to assess early metabolic response and to guide treatment of adenocarcinoma of the oesophagogastric junction: the MUNICON phase Ⅱ trial[J]. Lancet Oncol, 2007, 8(9): 797-805. DOI: 10.1016/S1470-2045(07)70244-9.
[8]Japanese Gastric Cancer Association. Japanese classification of gastric carcinoma: 3rd English edition[J]. Gastric Cancer, 2011, 14(2): 101-112. DOI: 10.1007/s10120-011-0041-5.
[9]刘坤, 李国立, 范朝刚, 等. 胃癌原发灶体积改变在胃癌术前化疗疗效评价中的应用价值[J]. 实用临床医药杂志, 2016, 20(24): 60-62, 72. DOI: 10.7619/jcmp.201624017.
[10] Nishino M, Jagannathan JP, Ramaiya NH, et al. Revised RECIST guideline version 1.1: what oncologists want to know and what radiologists need to know[J]. AJR Am J Roentgenol, 2010, 195(2): 281-289. DOI: 10.2214/AJR.09.4110.
[11] 唐磊, 孙应实, 李子禹, 等. 磁共振扩散加权成像表观扩散系数值与局部进展期胃癌新辅助化疗预后的关系[J]. 中华胃肠外科杂志, 2015, 18(3): 221-226. DOI: 10.3760/cma.j.issn.1671-0274.2015.03.006.
[12] 刘坤, 李国立, 范朝刚, 等. Choi标准在胃癌术前化疗疗效评价中的应用[J]. 实用临床医药杂志, 2016, 20(11): 54-58. DOI: 10.7619/jcmp.201611016.
[13] Kurokawa Y, Shibata T, Sasako M, et al. Validity of response assessment criteria in neoadjuvant chemotherapy for gastric cancer (JCOG0507A)[J]. Gastric Cancer, 2014, 17(3): 514-521. DOI: 10.1007/s10120-013-0294-2.
[14] Heger U, Bader F, Lordick F, et al. Interim endoscopy results during neoadjuvant therapy for gastric cancer correlate with histopathological response and prognosis[J]. Gastric Cancer, 2014, 17(3): 478-488. DOI: 10.1007/s10120-013-0296-0.
[15] Weber WA, Ott K, Becker K, et al. Prediction of response to preoperative chemotherapy in adenocarcinomas of the esophagogastric junction by metabolic imaging[J]. J Clin Oncol, 2001, 19(12): 3058-3065. DOI: 10.1200/JCO.2001.19.12.3058.
[16] Ott K, Fink U, Becker K, et al. Prediction of response to preoperative chemotherapy in gastric carcinoma by metabolic imaging: results of a prospective trial[J]. J Clin Oncol, 2003, 21(24): 4604-4610. DOI: 10.1200/JCO.2003.06.574.
[17] Becker K, Langer R, Reim D, et al. Significance of histopathological tumor regression after neoadjuvant chemotherapy in gastric adenocarcinomas: a summary of 480 cases[J]. Ann Surg, 2011, 253(5): 934-939. DOI: 10.1097/SLA.0b013e318216f449.
[18] 董元强, 汪志明. 胃癌新辅助化疗疗效预测方法及进展[J]. 国际外科学杂志, 2015, 42(10): 701-705. DOI: 10.3760/cma.j.issn.1673-4203.2015.10.018. |